AKERO LABS

akero-labs-logo

Akero is advanced data-driven, performance measurement software that measures every lead, every campaign and tracks every outcome.From humble beginnings in 2010 when Akero was known as Big Top, itโ€™s been a pretty awesome ride ever since.With a huge amount of dedication, talent and enthusiasm, along with the introduction of market leading features such as ad insights, tracking and automation, Akero continues to evolve at, quite frankly, an epic pace.

#People #Website #More

AKERO LABS

Social Links:

Industry:
Software

Founded:
2011-01-01

Address:
Portsmouth, New Hampshire, United States

Country:
United States

Website Url:
http://www.akerolabs.com

Total Employee:
11+

Status:
Active

Contact:
+44 (0)239 295 0008

Technology used in webpage:
Mobile Non Scaleable Content Euro Microsoft Exchange Online Amazon JsDelivr Cloudflare JS COVID-19 Apple Mobile Web App Capable Amazon Virginia Region Amazon Route 53


Current Employees Featured

steve-evans_image

Steve Evans
Steve Evans Founder @ Akero Labs
Founder
2009-01-01

Official Site Inspections

http://www.akerolabs.com Semrush global rank: 844.84 K Semrush visits lastest month: 45.07 K

  • Host name: server.onlineproof.website
  • IP address: 77.72.5.95
  • Location: United Kingdom
  • Latitude: 51.4964
  • Longitude: -0.1224
  • Timezone: Europe/London

Loading ...

More informations about "Akero Labs" on Search Engine

Akero Therapeutics | EFX for NASH | Metabolic Disease | Home

Twitter. Akero Therapeutics is a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH).See details»

Corporate Profile - Akero

Twitter. Corporate Profile. Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.See details»

Akero | LinkedIn

Akero | 1,472 followers on LinkedIn. The student media activation and conversion platform, powered by AI, supported by Higher Education experts. | Seamlessly connect your digital marketing spend...See details»

Akero Therapeutics Reports Statistically Significant Histological ...

Mar 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released preliminary topline week 96 results from โ€ฆSee details»

Campaigns - Akero

Akero Campaigns. AI powered student media plans, powered by billions of data points that deliver guaranteed results. Less Confusion. More Control. Control every element of your campaign, from content, creative and budgets โ€“ to the performance outcomes you need. Book a discovery call. Less Guesswork.See details»

Akero Therapeutics | Cardio-Metabolic Disease | EFX for NASH

About. Our Company. Our History. Leadership. Contact. Focus. Therapeutic Areas. Publications & Posters. Pipeline. Development Pipeline. Efruxifermin (EFX) Research Programs. Clinical Trials Overview. Expanded Access Policy. Careers. Our Culture. Job Opportunities. Investors & Media. Corporate Profile. Press Releases. Events & โ€ฆSee details»

Akero Therapeutics Announces Publication of Phase 2b โ€ฆ

Mar 7, 2024 SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with...See details»

Akero Therapeutics Reports Recent Highlights and Third Quarter โ€ฆ

PDF Version. SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today reported third quarter 2019 financial results for the period โ€ฆSee details»

Press Releases - Akero Therapeutics, Inc.

4 days ago Mar 04, 2024. Akero Therapeutics Announces Proposed Public Offering of Common Stock. Mar 04, 2024. Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study. Feb 29, 2024. Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study โ€ฆSee details»

Connect - Akero

Akero Connect. Get complete clarity on your recruitment funnel and reduce the cost of acquisition by up to 50%See details»

Net Natives | Akero

Akero. Learn more. We are trusted by: Play video Mute video. Change the way you work forever. Supercharge your enrollment operation. Get ahead of threats and opportunities. Frictionless advertising delivery. Awards. AI & Machine Learning Awards. 2022. UK Search Award. 2021. Digital.com. 2021. Drum Agency Business Awards.See details»

Case Studies - Akero

Case studies. Take a look at our Case Studies and see how we have helped other higher Education experts. How can you go beyond tracking clicks and impressions to see the bigger picture of advertising effectiveness? Can multiple data sources be integrated to understand the true cost per acquisition, from inquiry right through to enrollment?See details»

Unicursal Group - Crunchbase Company Profile & Funding

About. Our mission is to use data, technology and creativity to transform the way ambitious Universities inspire, connect and convert students. Brighton, East Sussex, United Kingdom. 101-250. Private. unicursal.group/ 1,126,018. Highlights. Employee Profiles 2. Similar Companies 6. Recent News & Activity.See details»

Convert - Akero

Book a discovery call. Fully supported by our Conversion experts. Less Guesswork. More Guarantees. Convert more of the right students for your institution. Convert your marketing/recruitment efforts into greater results. Convert guesswork into razor-sharp knowledge. Donโ€™t let your perfect students slip through your fingers.See details»

In wake of Winnipeg lab scandal, scientists say Canada benefits โ€ฆ

It will be the only non-government Level 4 facility in the country, part of the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO), which currently has a Level 3 lab.See details»

HOME | Neatly Ever After

At Neatly Ever After, we are committed to creating custom organizational systems that target the challenging areas of your home. We leave you with organizational solutions that last and are easily maintained by the whole family. Your customized solution can serve you in any part of your life - from your home, to your business, and even your ...See details»

Virginia CROs - Contract Research Map

601 Biotech Drive Suite 301 Richmond, Virginia, 23235 United States Granger Genetics, LLC is a contract research organization and clinical reference laboratory with in depth experience in molecular/ microbiology/ immunochemistry/ DNA sequencing. Our lab is supervised by a PhD trained scientist and is experienced working within regulatory โ€ฆSee details»

Akero | LinkedIn

Akero | 1,474 followers on LinkedIn. The student media activation and conversion platform, powered by AI, supported by Higher Education experts. | Seamlessly connect your digital marketing spend...See details»

TNO opens test lab for next generation battery technology

1 day ago 13 May 2024. On Monday, May 13th, TNO's Battery Lab at Holst Centre in Eindhoven was officially opened. Here, TNO experts research, develop and test next-generation battery technology together with companies. The aim is to prepare the technologies with and for companies for the next step to upscale towards mass production.See details»